Research
The numerous research opportunities available at Mount Sinai are a cornerstone of the Hematology/Medical Oncology Fellowship Program. Icahn School of Medicine at Mount Sinai is ranked 13th among medical schools in National Institutes of Health (NIH) funding for 2023. Fellows have 18 months of protected, mentored research time during the latter half of their fellowship. By the end of the first year of fellowship, fellows identify an area of interest and a mentor and are guided through the process of developing a research project. Our expectation is that fellow research projects will result in presentations at national conferences and publications and will equip fellows to apply for mentored training grants and other funding to allow them to further develop their interests and foster careers as academic leaders and independent investigators. Fellows are able to choose from a broad range of faculty mentors focusing on a diverse array of research (including basic science, translational, clinical, outcomes, quality improvement, and medical education) within the Division of Hematology/Medical Oncology, Tisch Cancer Institute or other institutes within The Icahn School of Medicine at Mount Sinai. To further guide fellows and their faculty mentors, Fellow Research Guidelines have been developed and Research Advisory Committees formed to outline expectations between mentors and mentees, provide timelines for research plans, progress reports, presentations and publications. Opportunities for advanced training in clinical research through the Masters in Clinical Research (MSCR) or Masters in Public Health (MPH) through the Graduate School for Biomedical Science at the Icahn School of Medicine are also available.
Selected Publications
By our faculty (in bold) and fellows (in pink)
Nathan DI, Feld J, El Jamal SM, Mascarenhas J, Tremblay D.
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Leuk Res. 2022 Apr;115:106820
Liu A, Rupani KV, Naymagon L.
Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.
Eur J Haematol. 2022 Jul;109(1):69-74
DOI: 10.1111/ejh.13770
Liu A, Phair J, Naymagon L.
Utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis
J Vasc Surg Venous Lymphat Disord. 2022 Jul;10(4):841-845
Tahri S, Mouhieddine TH, Redd R, Lampe L, El-Khoury H, Kham Su N, Nassar AH, Adib E, Bindra G, Abou Alaiwi S, Trippa L, Steensma DP, Castillo JJ, Treon SP, Ghobrial IM, Sperling AS.
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstrom Macroglobulinemia.
Blood Advances. 2021
DOI:10.1182/bloodadvances.2021004926
Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, Kappes K, PVI/Seronet, Mouhieddine TH, Wang B, Chari A, Cordon-Cardo C, Krammer F, Jagannath S, Simon V, Wajnberg A, Parekh S.
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021, 39 (8): 1028-1030.
DOI: 10.1016/j.ccell.2021.06.014
Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Awad MM, Mouw KW, Giannakis M, Hodi S, Shukla SA, Braun DA, Choueiri TK, Kwiatkowski DJ.
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research.
2021, 27 (14): 4025-4035
DOI: 10.1158/1078-0432.CCR-21-0575
Chaturvedi S, Antun AG, Farland A, Woods R, Metjian A, Park Y, de Ridder G, Gibson B, Kasthuri RS, Liles DK, Akwaa F, Clover T, Baumann Kreuziger L, Sadler JEE, Sridharan M, Go RS, McCrae KR, Upreti HV, Liu A, Lim MY, Gangaraju R, Zheng XL, Raval JS, Masias C, Cataland SR, Johnson AD, Davis E, Evans MD, Mazepa MA
Race, Rituximab, and Relapse in TTP.
Blood. 2022 Jul 7:blood.2022016640
DOI: 10.1182/blood.2022016640
Costa BA, Mouhieddine TH, Richter J.
What’s old is new: The past, present and future role of thalidomide in the modern-day management of multiple myeloma.
Targeted Oncology. 2022.
DOI: 10.1007/s11523-022-00897-8
Adib E, El Zarif T, Nassar AH, Akl EW, Abou Alaiwi S, Mouhieddine TH, Esplin ED, Hatchell K, Nielsen SM, Rana HQ, Choueiri TK, Kwiatkowski DJ, Sonpavde G.
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
British Journal of Cancer. 2022
DOI: 10.1038/s41416-021-01673-7
Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study. Blood. 2020 Jul 2;136(1):144-147
Zimmerman BS, Marcellino B, El Jamal SM, Renteria AS. Acquired Amegakaryocytic Thrombocytopenia as a Rare Cause of Thrombocytopenia during Pregnancy. BMJ Case Reports 2019; 12:1-4.
Lancman, G, Marcellino BK, Thibaud S, Troy K. Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19. Annals of Hematology (2020): 1-3.
Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M, Jagannath S, Parekh S, Madduri D. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematology Oncol. 2020 Jul 14;13(1):94.
Thibaud S, Tremblay D, Bhalla S, Zimmerman B, Sigel K, Gabrilove J. Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19. Br J Haematol 2020; 190(2):e73-e76.
Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A. BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database. Oncology 2020; 21: 1-4. DOI: 10.1159/000504965 PMID: 31962330
Feld J, Tremblay D, Thibaud S, Kessler A, Naymagon L. Ferritin levels in patients with COVID‐19: A poor predictor of mortality and hemophagocytic lymphohistiocytosis. International Journal of Laboratory Hematology (2020).
Naymagon L, Berwick B, Kessler A, Lancman G, Gidwani U, Troy K. The emergence of the methemoglobinemia amidst the COVID-19 pandemic. Am J Hematol 2020 Aug;95(8):E196-E197.
Sanchez L, Barley K, Richter J, Franz J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, Chari A. Immunomodulatory drug and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Expert Rev Hematol. 2020 Jul 30.
Richter J, Sanchez L, Thibaud S. Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date. Semin Oncol. 2020 Apr-Jun;47(2-3):155-164.
Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 Aug 7.
Patel VG, Zhong X, Liaw B, Tremblay D, Tsao CK, Galsky MD, Oh WK. Does androgen deprivation therapy protect against severe complications from COVID-19? Ann Oncol. 2020 Jul 9:S0923-7534(20)39933-6.
Venugopal S, Mascarenhas J, Steensma DP. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences. Blood Rev. 2020 Jul 23:100735.
Dharmapuri S, Özbek U, Lin JY, Sung M, Schwartz M, Branch AD, Ang C Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy. Cancer Med. 2020 Jul;9(14):4962-4970.
Marcellino BK, Mascarenhas J SLAM dunk for myelofibrosis? Blood. 2019 Sep 5;134(10):789-791.
Mascarenhas J, Marcellino BK, Lu M, Kremyanskaya M, Fabris F, Sandy L, Mehrotra M, Houldsworth J, Najfeld V, El Jamal S, Petersen B, Moshier E, Hoffman R A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). Leuk Res. 2020 Jan;88:106272.
Naymagon L, Marcellino B, Mascarenhas J Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Rev. 2019 Jul;36:23-31. Epub 2019 Mar 30.
Kessler AJ, Marcellino BK, Niglio SA, Petersen BE, Malone AK. A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. Case Rep Hematol. 2019 Feb 13.
Contact Us
Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place Box 1079 New York, NY 10029 (212) 241-4705